在癌症中记录和分类MET受体突变
1Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.
eLife
|April 23, 2024
概括
氨酸激酶抑制剂 (TKIs) 的最新进展针对非小细胞肺癌 (NSCLC) 中的MET突变. 了解MET突变是开发有效的癌症治疗方法和克服耐药性的关键.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 在各种癌症中,MET受体氨酸激酶 (RTK) 经常被放松调节,从而促进瘤的进展.
- 首个与癌症相关的MET突变是在1997年在遗传性乳头性癌 (HPRC) 中发现的.
- 转基因突变,特别是酶域中的突变,通常会导致连接体独立激活.
研究的目的:
- 审查MET突变在癌症发展中的表征.
- 概述新型MET突变的发现和影响,包括14号外跳转.
- 讨论预测新发现的MET突变的转化活动和TKI敏感性的挑战.
主要方法:
- 对癌症中MET突变的文献综述.
- 分析MET突变对受体激活和癌症进展的影响.
- 针对MET的治疗策略的审查,包括氨酸激酶抑制剂 (TKI).
主要成果:
- 针对MET的氨酸激酶抑制剂 (TKI) 已被批准用于具有特定MET突变的高级非小细胞肺癌 (NSCLC).
- 2014年发现的MET外显子14跳转突变,代表了一类独特的MET变异.
- 虽然MET TKIs在MET外显子14跳转的NSCLC中表现出有效性,但涉及新的MET突变的耐药性机制已经出现.
结论:
- 发现和描述MET突变对于推进癌症治疗至关重要.
- 持续的研究对于理解新型MET突变及其对技术知识的反应至关重要.
- 预测MET突变的转化潜力和TKI敏感性对于个性化癌症治疗策略至关重要.
更多相关视频
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
24.3K
10:57Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay
Published on: August 14, 2018
10.7K
相关概念视频
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Mutagenicity and Carcinogenicity
1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Mutations
37.0K
Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
37.0K
